Connect with us
MARE BALTICUM Gaming & TECH Summit 2024

Artificial Intelligence

Aramis Biosciences Launches to Address Unmet Needs in Ocular Immunology

Published

on

Founded by Renowned Experts in Ophthalmology and Immunology

Launches with $10.5 million Series A Financing Led by Safar Partners to Advance Disease-Modifying Therapy for Ocular Surface Disease into the Clinic

BOSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) — Aramis Biosciences, Inc., a clinical-stage immuno-ophthalmology biopharmaceutical company, today announced its launch and the completion of a $10.5 million Series A financing led by Safar Partners with a strategic investment from a global leader in ophthalmic pharmaceuticals. Proceeds from the financing will be used to advance the company’s pipeline, including its lead product candidate, A197, a novel, first-in-class, topical immunomodulatory agent licensed from Dompé farmaceutici, through Phase II clinical proof of concept for the treatment of dry eye disease.

Aramis Biosciences was founded by leading experts in the fields of corneal disorders, ocular inflammation and immunology, Reza Dana, M.D., M.P.H., M.Sc. and Sunil Chauhan, D.V.M., Ph.D., following more than a decade of research at The Schepens Eye Research Institute of Mass Eye and Ear and Department of Ophthalmology at Harvard Medical School, where the role of a certain subset of pro-inflammatory T helper cells were found to be central to the immunopathogenesis of dry eye disease. This discovery was made possible by more than $9 million in non-dilutive federal grant funding and is the subject of extensive peer-reviewed publications in leading scientific journals.

“Dry eye disease is the number one non-refractive reason why patients seek eye care, but less than 5 percent of patients are currently treated with an FDA-approved product due to suboptimal efficacy and tolerability limitations commonly associated with these products. Aramis Biosciences was founded to address this treatment gap with A197, a new molecular entity promising a rapid onset of action, a durable, disease-modifying effect and a clean tolerability profile,” said Reza Dana, M.D., M.P.H., M.Sc., Scientific Co-Founder of Aramis Biosciences.  

World-Renowned Experts in Corneal Disorders, Ocular Inflammation and Immunology

Dr. Dana is an internationally recognized expert in corneal disorders, ocular inflammation and immunology who holds the Claes Dohlman Chair in Ophthalmology at Harvard Medical School. He is Director of the Cornea Service at Mass Eye and Ear, Senior Scientist at Schepens Eye Research Institute of Mass Eye and Ear where he leads the Laboratory of Corneal Immunology, Transplantation and Regeneration, and is a member of the Harvard Medical School Committee on Immunology. Dr. Chauhan, an expert in immune modulation and stem cell biology, is Associate Professor of Ophthalmology at Harvard Medical School and Associate Scientist at The Schepens Eye Research Institute of Mass Eye and Ear.

Validating Partnerships

In addition to its strong scientific foundation from Mass Eye and Ear and a strategic investment from a global leader in ophthalmic pharmaceuticals, Aramis Biosciences boasts Dompé farmaceutici S.p.A. as a shareholder and the licensor of its lead product candidate, A197. Through its exclusive global license agreement, Aramis Biosciences has secured from Dompé the global ophthalmic rights to this novel, first-in-class, topical immunomodulatory agent. Furthermore, Aramis Biosciences has leveraged Dompé’s extensive research and development capabilities through an additional financial and operational resource partnership to complete all IND-enabling preclinical studies, CMC development and providing Phase II clinical supply of A197.

“We are thrilled to see how our EXSCALATE artificial intelligence platform was able to rapidly identify a new molecular entity meeting the very challenging specifications for an immunomodulatory agent with optimal characteristics for topical delivery to the ocular surface,” said Marcello Allegretti, Chief Scientific Officer of Dompé. “Leveraging our deep know-how on cytokine and chemokine targets, EXSCALATE enabled the Aramis Biosciences team to accelerate the process from target identification to IND significantly faster than is typically seen. We look forward to following the clinical translation of A197’s promising preclinical results next year.”

Accomplished Leadership

Aramis Biosciences is led by an experienced management team, with 30-year pharmaceutical/med-tech veteran, David S. Tierney, M.D., as President and CEO, and has assembled a board of directors and medical advisory board with a proven track record of building and creating value at successful life sciences companies. Prior to Dr. Tierney’s appointment as President and CEO of Aramis Biosciences, he served as President and CEO of Pharma Two B, BioPharmX Corporation and Icon Bioscience, Inc., now EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), where he led a team that in 2018 received U.S. FDA approval of its New Drug Application for DEXYCU™ (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery. Dr. Tierney served as President and COO of Oceana Therapeutics, Inc., a specialty therapeutic company he co-founded in 2008. Oceana quickly established a global commercial network and by 2011 was acquired by Salix Pharmaceuticals, now Bausch Health. Under his leadership, Valera Pharmaceuticals grew into a fully integrated, commercial, specialty pharma company that successfully completed an initial public offering in 2006. Valera has since been merged into Endo Pharmaceuticals. Earlier in his career, he served as senior vice president of drug development at Roberts Pharmaceutical prior to its acquisition by Shire Pharmaceuticals, now Takeda, and held a variety of management positions at Elan Corporation, now Perrigo. Dr. Tierney received his medical degree from Royal College of Surgeons in Ireland.

David S. Tierney, M.D., Aramis Biosciences’ President and CEO commented, “We look forward to entering Phase 2 clinical trials with A197. With unparalleled science and strategic support from Safar, Dompé, and a global leader in ophthalmic pharmaceuticals, the team at Aramis Bio is committed to delivering this promising investigational therapy to dry eye patients worldwide.”

About Aramis Biosciences

Aramis Biosciences is a clinical-stage immuno-ophthalmology biopharmaceutical company committed to the development of disease-modifying therapy for ocular surface disease. For more about Aramis Biosciences, visit https://www.aramisbio.com.

About Safar Partners

Safar Partners is a seed- to growth-stage venture fund investing primarily in technology companies out of Harvard, Massachusetts Institute of Technology, and the University of Rochester.

With access to the most promising technologies developed by the brightest minds, Safar is often one of the first investors in its portfolio companies, helping them grow and achieve technological and financial success. Its board is comprised of scholars and experts from Harvard, Massachusetts Institute of Technology, and the University of Rochester who are committed to seeing a more efficient technology transfer and faster scaling of ideas that will change the world. For more about Safar Partners, visit https://www.safar.partners.

About Dompé farmaceutici, S.p.A.

Dompé farmaceutici, S.p.A. is a private, rapidly scaling global biopharmaceutical company founded in Milan, Italy, with a 130-year legacy of medical innovation. The company is a leader in research and discovery in inflammation and immunology in specific mechanisms underlying conditions of significant unmet medical need including the first medication based on recombinant human Nerve Growth Factor. Dompé’s research and development is anchored by EXSCALATE, a structure-based virtual screening platform developed in-house that leverages one of the most powerful supercomputing and artificial intelligence platforms in the world and has been shown to significantly reduce the time to IND submission. Today, Dompé employs more than 800 employees worldwide and maintains a U.S. commercial operations hub in the San Francisco Bay Area as well as an R&D presence in Boston. For more about Dompé, visit https://www.dompe.com.

Contacts

David S. Tierney, M.D.
President and CEO
[email protected]

For inquiries on Dompé farmaceutici and EXSCALATE:

Guido Romeo – Head Corporate Communications
Mob. +39 349 4154010
[email protected]

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Artificial Intelligence

TREEFROG THERAPEUTICS PICKS-UP BEST POSTER AWARD AT THE INTERNATIONAL SOCIETY FOR CELL & GENE THERAPY (ISCT) ANNUAL MEETING FOR THEIR CELL THERAPY PROGRAM IN PARKINSON’S DISEASE

Published

on

treefrog-therapeutics-picks-up-best-poster-award-at-the-international-society-for-cell-&-gene-therapy-(isct)-annual-meeting-for-their-cell-therapy-program-in-parkinson’s-disease

–  Treefrog will present two posters on their cell therapy program in Parkinson’s Disease and their proprietary encapsulation technology, C-Stem™ –  
BORDEAUX, France, May 29, 2024 /PRNewswire/ — TreeFrog Therapeutics has a busy schedule at the ISCT’s 30th annual meeting, taking place in Vancouver, Canada this week, with two posters being presented, one of which has been awarded the Best Poster in the iPSC category. A poster on their transformational encapsulation technology, C-Stem™, will also be presented. 

TreeFrog is a cell therapy company with a lead program in Parkinson’s disease, a complex neurodegenerative disease with no cure and treatments that offer symptomatic relief only. Decades of research demonstrate that cell therapy holds immense promise for Parkinson’s disease, with multiple clinical trials ongoing. However, the manufacturing of these cells must overcome major pharmaceutical challenges, including scalability, to be compatible with potential commercial phases. The cell therapy program at TreeFrog is based on C-Stem™, a proprietary technology platform that overcomes these challenges. In 2021, the company achieved a world-first of producing 15billion iPSCs in one run, in one week.
Michael Lanero Fidalgo, Chief Operating Officer, will represent the company for the Best Poster in the iPSC category, an award designed to recognize outstanding abstracts related to iPSC research. Poster #1219, First Off-The-Shelf Bioreactor Produced, iPSC-Derived Neural Microtissues Containing Dopaminergic Neurons Innervate the Striatum and Normalize Behavior in a Parkinson Rat Model, is also one of only twenty posters chosen for an elevator pitch presentation from the overall 600 considered.
Kevin Alessandri, co-founder and Chief Technology Officer, will present poster #1200 Cell encapsulation as a tool for stem cell-based cell therapy industrialization, a deep dive into how the C-Stem™ technology, can overcome the bottlenecks of the complex Chemistry, Manufacturing and Controls (CMC) in cell therapy. He will also participate as a KOL in the JSRM-ISCT iPSC workshop event iPSCs: From Bench to Bedside’ Scientific Signature Series.
Events:
Elevator Pitch presentation by Michael Lanero-Fidalgo, representing lead authors Nicolas Prudon & Lucia Cordero Espinoza May 29th, 2024 @ 12:00 – 13:00, Room 201iPSC Poster Presentation Networking reception (Posters #1219 & #1200) May 30th @ 18:00 – 19:30 Exhibit & Poster HalliPSC: Bench to Bedside: Scientific Signature Series, participation of Kevin Alessandri as KOL. June 1st, 2024 @ 7:30 – 16:00, Room 212-214www.treefrog.fr
CONTACT:  Rachel MooneyChief Communications OfficerTreeFrog Therapeutics [email protected]  
Logo – https://mma.prnewswire.com/media/2272329/treefrog_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/treefrog-therapeutics-picks-up-best-poster-award-at-the-international-society-for-cell–gene-therapy-isct-annual-meeting-for-their-cell-therapy-program-in-parkinsons-disease-302156935.html

Continue Reading

Artificial Intelligence

US Air Force Awards ThroughPut.ai Direct-to-Phase-II Contract for Boeing, Lockheed Martin, and Sikorsky Mission Design Series to Accelerate Aircraft Readiness

Published

on

us-air-force-awards-throughput.ai-direct-to-phase-ii-contract-for-boeing,-lockheed-martin,-and-sikorsky-mission-design-series-to-accelerate-aircraft-readiness

Leveraging Data to Drive Maintenance-first actions that improve overall supply chain throughput across the DAF.
NEW YORK, May 28, 2024 /PRNewswire/ — ThroughPut.ai, the Supply Chain Decision Intelligence Pioneer, announces it has been selected by AFWERX for a (SBIR Direct-to-Phase II contract) in the amount of $1,248,627.00 focused on “AI-Powered Proactive Supply Chain Capabilities” to address the most pressing challenges in the Department of the Air Force (DAF). The Air Force Research Laboratory and AFWERX have partnered to streamline the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) process by accelerating the small business experience through faster proposal to award timelines, changing the pool of potential applicants by expanding opportunities to small business and eliminating bureaucratic overhead by continually implementing process improvement changes in contract execution. The DAF began offering the Open Topic SBIR/STTR program in 2018 which expanded the range of innovations the DAF funded and now on April 17th, 2024, ThroughPut.ai will start its journey to create and provide innovative capabilities that will strengthen the national defense of the United States of America.

“ThroughPut.ai looks forward to supporting efforts to accelerate inventory flow across the United States Air Force,” said Ali Raza, CEO & Founder of ThroughPut.ai. “By driving inventory/materiel management changes at the maintenance endpoint first, supply chain improvements can then be amplified across the greater industrial base to create aircraft capacity.”
“The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government.”
About (ThroughPut.ai)
ThroughPut.ai is a Silicon Valley-based supply chain optimization & predictive replenishment company. The company’s software AI platform has the ability to identify location-, product-, and customer-based demand changes sooner in order to adjust order frequencies, vendor sources, and parts buffer levels at a global and local scale. ThroughPut’s platform was designed by Fortune 500 & technology executives with real-world experience managing demand & supply chain disruptions and war-zone logistics across the Middle East.
About AFRLThe Air Force Research Laboratory is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development, and integration of affordable warfighting technologies for our air, space and cyberspace force. With a workforce of more than 12,500 across nine technology areas and 40 other operations across the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit afresearchlab.com.
About AFWERXAs the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at five hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has executed over 6,100 new contracts worth more than $4 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit: www.afwerx.com. 
Company Press Contact:Ali RazaCEO/[email protected] 

View original content:https://www.prnewswire.co.uk/news-releases/us-air-force-awards-throughputai-direct-to-phase-ii-contract-for-boeing-lockheed-martin-and-sikorsky-mission-design-series-to-accelerate-aircraft-readiness-302156930.html

Continue Reading

Artificial Intelligence

Data Center Investments Soar: 200% Rise Since 2016 and Projected 89% Increase by 2028

Published

on

data-center-investments-soar:-200%-rise-since-2016-and-projected-89%-increase-by-2028

USA News Group CommentaryIssued on behalf of Avant Technologies Inc.
VANCOUVER, BC, May 28, 2024 /PRNewswire/ — Since 2016, investment in data centre infrastructure has risen 200%, with a further 89% increase expected by 2028 as more opportunities emerge with the rise of artificial intelligence (AI). According to Jones Lang LaSalle Inc.’s CEO Christian Ulbrich, data centers are “the hottest asset class at the moment.” Analysts at Technavio are projecting the global data center market to record an additional US$329.82 billion in growth at a CAGR of 12.73% through 2027. Capitalizing on the opportunity are several players recently announcing developments regarding their involvement in the data centers sector, including

Avant Technologies Inc. (OTCQB: AVAI), Amazon.com, Inc. (NASDAQ: AMZN), Applied Digital Corporation (NASDAQ: APLD), Digital Realty Trust, Inc. (NYSE: DLR), and Equinix, Inc. (NASDAQ: EQIX).
As an early pioneer in generative AI, Avant Technologies Inc. (OTCQB: AVAI) continues to enhance its flagship asset, Avant AITM, a sophisticated machine and deep learning AI system designed for versatility and customization across various industries and applications. Recently, Avant announced plans to equip its AI-managed data center, currently in development, with High-Performance Computing (HPC) systems. According to IBM, HPC technology utilizes clusters of powerful processors working in parallel to process massive multi-dimensional data sets and solve complex problems at exceptionally high speeds.
“The rise of AI is revolutionizing industries, and Avant Technologies is committed to being at the forefront of this transformation,” said William Hisey, CEO of Avant. “By building an AI-managed data center with HPC systems, we will gain the computational power and infrastructure required to train and deploy sophisticated AI models, which will ultimately provide even greater value to our customers.”
The new data center will leverage AI-driven management technology to optimize resource allocation and enhance efficiency in all aspects of data center operations. Avant will meticulously design its HPC infrastructure to meet the demands of AI workloads, selecting high-performance CPUs and GPUs (or TPUs) specifically suited for deep learning tasks. This cutting-edge facility will enable Avant to accelerate AI advancements, delivering innovative solutions to clients by improving data center efficiency and empowering them with exceptional AI capabilities.
Additionally, Avant will implement a high-speed network to ensure efficient data transfer and select a scalable storage solution to manage the large datasets necessary for training and utilizing AI models. The HPC systems will prioritize security, incorporating robust measures to protect sensitive data and create a secure environment for AI deployment. Furthermore, the data center will integrate energy-efficient technologies and sustainable design practices, reflecting Avant’s commitment to environmental responsibility.
Avant Technologies also recently announced plans to implement AI-empowered Zero Trust Architecture (ZTA) across its data center operations. Additionally, the company has expanded its AvantAI™ platform to include intelligent, proactive monitoring and management for data centers.
Over the past few weeks Amazon.com, Inc. (NASDAQ: AMZN) has collectively committed to investing $20 billion into new data centers for its subsidiary Amazon Web Services (AWS). The first to be announced was an $11-billion data center to be built in Indiana, with another $9 billion set to accelerate cloud-infrastructure in Singapore. The moves fall in line with Amazon CEO Andy Jassy’s projection that 85% of IT spending will remain on premises, in the race for Gen AI supremacy.
Amazon also recently announced an extension on its partnership between AWS and CrowdStrike to unify cybersecurity protection on its CrowdStrike Falcon platform. As per the agreement, Amazon is replacing a variety of cloud point products with Falcon Cloud Security, is using Falcon Next-Gen SIEM to secure big data logging and is deploying Identity Threat Detection and Response to prevent identity-based attacks.
“CrowdStrike and AWS have a deep history of working together to secure the most innovative companies in the world,” said CJ Moses, Chief Information Security Officer and Vice President of Security Engineering at Amazon. “Amazon uses CrowdStrike to provide visibility, detection, and response across our businesses in order to protect the cloud, infrastructure, and services for our customers. This is part of our shared mission to help all organizations build, operate, and secure their business.”
In a move to shore-up its market position as a designer, builder, and operator of next-generation digital infrastructure designed for High-Performance Computing (“HPC”) applications, Applied Digital Corporation (NASDAQ: APLD) recently announced the appointment of industry veteran Todd Gale as its new Chief Development Officer. The announcement came just one month after the company announced it had issued a $50 million unsecured convertible debenture to advance its HPC Data Center Project in Ellendale, North Dakota.
“We intend to use the net proceeds from the private financing, supplemented by the proceeds from our announced sale of the Garden City facility, to finance substantial advancements in our construction phase of the HPC data center in Ellendale, North Dakota,” said David Rench, CFO of Applied Digital. “Concurrently, we continue negotiating our project-level financing to ensure timely project completion and fulfillment of our contractual obligations.”
Applied Digital intends to utilize chipmaking giant NVIDIA’s new Blackwell platform into its cloud offerings. The company’s next-generation data center campuses are specifically designed to host HPC/AI applications, offering more cost-effective and efficient alternatives to traditional data centers.
In Japan, Digital Realty Trust, Inc. (NYSE: DLR) recently announced the expansion of its NRT Campus, by commencing construction of its third data center to support AI. Upon completion of the site in late 2025, the campus’s capacity will rise to 104MW, with the intention of meeting rising demand for next-generation infrastructure, and seamless access to Japan’s connected data communities.
“Japan’s rapidly increasing demand for AI deployments creates the need for scalable, flexible, and highly connected AI-ready data centers in the Tokyo metropolitan area,” said Serene Nah, Managing Director and Head of Asia Pacific, Digital Realty. “We believe NRT14’s next-generation data center infrastructure and Digital Realty’s connected global open data center platform provide the foundational pillars our customers need to drive innovation in the coming years.”
Equinix, Inc. (NASDAQ: EQIX), another digital infrastructure company, has recently launched a $600 million joint venture with PGIM Real Estate to develop and operate the first xScale data center in the US, situated in California’s Silicon Valley. This follows their successful collaboration on the first xScale data center in Australia in 2022, which was part of a similar $575 million joint venture announced in 2021.
Under the terms of the new agreement, PGIM Real Estate will hold an 80% equity interest in the joint venture, while Equinix will retain a 20% equity stake. xScale data centers by Equinix enable hyperscale companies to expand their core deployments within Equinix’s IBX data centers, facilitating growth in over 70 global metros through a platform that supports direct interconnections with more than 10,000 customers.
This joint venture complements Equinix’s existing hyperscale collaborations in Europe, Asia-Pacific, and the Americas, significantly enhancing the global xScale data center portfolio. Once completed, this global expansion is set to exceed $8 billion, encompassing more than 35 facilities and providing over 725 megawatts of power capacity.
Source: https://usanewsgroup.com/2023/10/26/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 
CONTACT:USA NEWS [email protected](604) 265-2873
DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (“MIQ”). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased as a part of a private placement. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through further private placements and/or investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

View original content:https://www.prnewswire.co.uk/news-releases/data-center-investments-soar-200-rise-since-2016-and-projected-89-increase-by-2028-302156928.html

Continue Reading

Trending